ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden
- Resource Type
- Authors
- Yuan-Yeh Kuo; Ming Yao; Yu-Hung Wang; Fen-Ming Tien; Hwei-Fang Tien; Ko-Ping Chang; Yun-Chu Lin; Chung-Wu Lin; Jih-Luh Tang; Sze-Hwei Lee; Tai-Chung Huang; Hsin-An Hou; Cheng-Hong Tsai; Chien-Chin Lin; Wen-Chien Chou; Shan-Ju Wu
- Source
- Blood Cancer Journal
Blood Cancer Journal, Vol 10, Iss 10, Pp 1-4 (2020)
- Subject
- Oncology
Male
medicine.medical_specialty
Poor prognosis
Mutation, Missense
Myeloproliferative disease
lcsh:RC254-282
Disease-Free Survival
Internal medicine
Correspondence
medicine
Humans
Allele
Myelofibrosis
Cancer genetics
Alleles
Aged
Retrospective Studies
business.industry
Hematology
Janus Kinase 2
Middle Aged
medicine.disease
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Repressor Proteins
Survival Rate
Amino Acid Substitution
Primary Myelofibrosis
Mutation (genetic algorithm)
Female
business
- Language
- English
- ISSN
- 2044-5385